Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Pidala

Showing results (1-10 of 198) with videos related to

Pageof 20
Sort By:
Cancer Control : Journal of the Moffitt Cancer Center|October 7, 2011
Progress in hematopoietic cell transplantationJoseph Pidala
Cancer Control : Journal of the Moffitt Cancer Center|October 7, 2011
Graft-vs-host disease following allogeneic hematopoietic cell transplantationJoseph Pidala
Blood|February 2, 2023
Progress in risk-adapted acute GVHD therapyJoseph Pidala
Blood|July 9, 2016
Predicting relevant immunogenetic disparitiesJoseph Pidala, Claudio Anasetti
Haematologica|May 13, 2022
Fine-tuning alloreactivity against HLA-DP to control leukemia with tolerable graft-<i>versus</i>-host diseaseJoseph Pidala, Claudio Anasetti
Haematologica|December 18, 2009
Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse?Joseph Pidala, Claudio Anasetti
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 26, 2010
Glucocorticoid-refractory acute graft-versus-host diseaseJoseph Pidala, Claudio Anasetti
Pharmacotherapy|May 23, 2020
Evolving Therapeutic Options for Chronic Graft-versus-Host DiseaseRebecca M Gonzalez, Joseph Pidala
Current Opinion in Hematology|September 14, 2011
Have we improved in preventing and treating acute graft-versus-host disease?Lia Perez, Claudio Anasetti, Joseph Pidala
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 23, 2009
Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantationJoseph Pidala, Jongphil Kim, Claudio Anasetti
Pageof 20

Showing results (1-10 of 198) with videos related to

Sort By:
Pageof 20
Cancer Control : Journal of the Moffitt Cancer Center|October 7, 2011
Progress in hematopoietic cell transplantationJoseph Pidala
Cancer Control : Journal of the Moffitt Cancer Center|October 7, 2011
Graft-vs-host disease following allogeneic hematopoietic cell transplantationJoseph Pidala
Blood|February 2, 2023
Progress in risk-adapted acute GVHD therapyJoseph Pidala
Blood|July 9, 2016
Predicting relevant immunogenetic disparitiesJoseph Pidala, Claudio Anasetti
Haematologica|May 13, 2022
Fine-tuning alloreactivity against HLA-DP to control leukemia with tolerable graft-<i>versus</i>-host diseaseJoseph Pidala, Claudio Anasetti
Haematologica|December 18, 2009
Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse?Joseph Pidala, Claudio Anasetti
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 26, 2010
Glucocorticoid-refractory acute graft-versus-host diseaseJoseph Pidala, Claudio Anasetti
Pharmacotherapy|May 23, 2020
Evolving Therapeutic Options for Chronic Graft-versus-Host DiseaseRebecca M Gonzalez, Joseph Pidala
Current Opinion in Hematology|September 14, 2011
Have we improved in preventing and treating acute graft-versus-host disease?Lia Perez, Claudio Anasetti, Joseph Pidala
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 23, 2009
Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantationJoseph Pidala, Jongphil Kim, Claudio Anasetti
Pageof 20